News articles about ContraVir Pharmaceuticals (NASDAQ:CTRV) have been trending somewhat negative this week, Alpha One reports. Alpha One, a service of Accern, rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ContraVir Pharmaceuticals earned a media sentiment score of -0.08 on Alpha One’s scale. Alpha One also assigned news articles about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have effected Alpha One’s analysis:
- ContraVir Pharmaceuticals Inc (CTRV) Moving -4.60% in Session (trikkles.com)
- Zooming in on the Numbers for ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) – Jonesboro Recorder (jonesbororecorder.com)
- ContraVir Pharmaceuticals, Inc. (CTRV) Share Price Could Be Rising After -42.08% fall In 2017 – StockNewsMagazine (stocknewsmagazine.com)
- Needle Action Activity Spotted in ContraVir Pharmaceuticals Inc (CTRV) – Wall Street Review (thewallstreetreview.com)
- ContraVir Pharmaceuticals to Present at 2017 BIO International Convention (finance.yahoo.com)
Shares of ContraVir Pharmaceuticals (NASDAQ:CTRV) opened at 0.6271 on Friday. ContraVir Pharmaceuticals has a 1-year low of $0.60 and a 1-year high of $2.65. The stock’s market capitalization is $39.95 million. The stock has a 50 day moving average of $0.68 and a 200-day moving average of $1.32.
A number of research firms have recently issued reports on CTRV. Maxim Group set a $4.00 price target on shares of ContraVir Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, April 11th. Noble Financial reissued a “buy” rating on shares of ContraVir Pharmaceuticals in a research note on Friday, April 21st.
WARNING: “ContraVir Pharmaceuticals (CTRV) Receiving Somewhat Negative News Coverage, Report Shows” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://transcriptdaily.com/2017/06/17/contravir-pharmaceuticals-ctrv-receives-daily-news-impact-score-of-0-08-updated.html.
ContraVir Pharmaceuticals Company Profile
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.
Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.